Аналитики повысили рейтинг акций биотехнологической компании INmune Bio на фоне роста интереса институциональных инвесторов

Акции INmune Bio подорожали после того, как аналитики Wall Street Zen и Weiss Ratings улучшили свои прогнозы, а компания отчиталась о прибыли, превысив ожидания рынка. Крупные инвестиционные фонды, включая Royal Bank of Canada и Geode Capital Management, значительно увеличили свои доли в компании в первом квартале.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

INmune Bio, Inc. (NASDAQ:INMB – Get Free Report)’s stock price traded down 1.3% on Monday . The stock traded as low as $2.21 and last traded at $2.30. Approximately 294,749 shares traded hands during trading, a decline of 25% from the average daily volume of 390,631 shares. The stock had previously closed at $2.33. Analysts Set New Price Targets INMB has been the topic of several recent research reports. Weiss Ratings upgraded shares of INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 19th. Wall Street Zen upgraded shares of INmune Bio from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, INmune Bio currently has a consensus rating of “Moderate Buy”. Read Our Latest Stock Report on INmune Bio INmune Bio Price Performance INmune Bio (NASDAQ:INMB – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.16. Hedge Funds Weigh In On INmune Bio A number of institutional investors and hedge funds have recently modified their holdings of INMB. Royal Bank of Canada increased its stake in shares of INmune Bio by 44.8% in the 1st quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock valued at $233,000 after acquiring an additional 9,236 shares in the last quarter. Jane Street Group LLC acquired a new stake in INmune Bio in the first quarter worth $142,000. Rhumbline Advisers increased its stake in INmune Bio by 14.4% in the first quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock valued at $150,000 after purchasing an additional 2,409 shares in the last quarter. Geode Capital Management LLC increased its stake in INmune Bio by 6.9% in the second quarter. Geode Capital Management LLC now owns 389,931 shares of the company’s stock valued at $901,000 after purchasing an additional 25,069 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of INmune Bio during the second quarter valued at about $26,000. 12.72% of the stock is currently owned by institutional investors. INmune Bio Company Profile INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions. The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions. Featured Articles Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.